Trial Profile
Phase 2 Study of Denosumab (NSC 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- 18 Jan 2024 Status changed from active, no longer recruiting to completed.
- 18 Dec 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.
- 29 Dec 2022 Planned End Date changed from 30 Sep 2022 to 30 Sep 2023.